GLP-1s Aren't "Skinny Shots": Retatrutide, CKM & the Future of Obesity Care

<p>GLP-1 medications have become some of the most talked about drugs in medicine—but are they really just &quot;skinny shots&quot;?</p><p>In this episode of <strong>Weight &amp; Measure with Mike and Zach</strong>, we sit down with two of the most respected voices in obesity care to separate fact from fiction and explore where obesity treatment is heading next.</p><p>Joining us are:</p><p><strong>Ted Kyle, RPh, MBA</strong> – Founder of ConscienHealth and one of the nation&#39;s leading advocates for evidence-based obesity policy and public education.</p><p><strong>Katherine Saunders, MD, DABOM</strong> – Obesity Medicine physician and nationally recognized expert on GLP-1 medications, emerging obesity therapies, and comprehensive obesity care.</p><p>Together, we discuss why GLP-1 medications are changing much more than body weight, how obesity medicine is shifting its focus toward overall health, and why the next generation of therapies—including <strong>retatrutide</strong>—could reshape obesity treatment once again.</p><p>• Why calling GLP-1s &quot;skinny shots&quot; misses the bigger picture.<br>• How GLP-1 medications are changing healthcare, society, and the conversation around obesity.<br>• Why obesity is a chronic disease—and why that idea still faces resistance.<br>• What CKM (Cardiovascular, Kidney, and Metabolic Health) means and why it&#39;s becoming a new framework for treating patients.<br>• The latest research on access to obesity care and what the &quot;secret shopper&quot; study revealed.<br>• How social media has influenced public understanding of obesity, for better and for worse.<br>• The science behind glucagon agonists, amylin agonists, and combination therapies.<br>• Why <strong>retatrutide</strong> has generated so much excitement—and why experts caution that more weight loss doesn&#39;t automatically mean a better medication.<br>• How GLP-1 medications fit alongside <strong>metabolic and bariatric surgery</strong> as part of comprehensive, individualized obesity care.<br>• What today&#39;s obesity experts hope we&#39;ll understand differently about GLP-1s twenty years from now.</p><p>Whether you&#39;re living with obesity, taking a GLP-1 medication, considering metabolic and bariatric surgery, following the latest research on <strong>retatrutide</strong>, or simply trying to better understand obesity as a chronic disease, this conversation provides practical, evidence-based insights grounded in science—not stigma.</p><p>• Ted Kyle, RPh, MBA<br>• Katherine Saunders, MD, DABOM</p><p>GLP-1 • GLP-1 medications • Retatrutide • Tirzepatide • Semaglutide • Ozempic • Wegovy • Mounjaro • Zepbound • Obesity Medicine • Obesity Care • Chronic Disease • CKM • Cardiovascular Kidney Metabolic Health • Metabolic and Bariatric Surgery • Weight Loss Medications • Anti-Obesity Medications • Emerging Obesity Therapies • Glucagon Agonists • Amylin Agonists • Comprehensive Obesity Care • Weight Bias • Obesity Advocacy • Patient Advocacy • Evidence-Based Medicine</p><p>If you enjoyed this conversation, be sure to subscribe to <strong>Weight &amp; Measure</strong> on YouTube and follow us on <strong>Spotify, Apple Podcasts, and Amazon Music</strong> so you never miss future conversations exploring the science of obesity, GLP-1 medications, metabolic and bariatric surgery, and the future of evidence-based obesity care.</p><p><strong>More Science. Less Stigma.</strong></p>